Newsletter | December 13, 2025

12.13.25 -- Best Of November

NOVEMBER'S BEST FEATURED EDITORIAL

Reading The FDA Tea Leaves On Psychedelics

By Ben Comer, Chief Editor, Life Science Leader

MAPS founder Rick Doblin accused the FDA of changing the goal posts after Lykos's MDMA Complete Response Letter was released, and offered insights for other psychedelic developers.

NOVEMBER'S BEST INDUSTRY INSIGHTS

The Future Of Clinical Research Enrollment: A Patient-Centric Approach

To address challenges such as limited patient awareness, mistrust, and logistical barriers, the industry must embrace technology-driven solutions and community-centered outreach.

A New Take On The Evolving Role Of AI In Clinical Trials

Artificial intelligence is shifting from promise to practice in biopharma. Zhong Lu, director of data science and AI at Novartis, outlines how AI is evolving the clinical trials process end-to-end.

Emerging Vaccine Technologies Require Broad CDMO Expertise

Rapidly shifting modalities require broad CDMO expertise and capacity, and commercializing recombinant vector vaccines requires a skill set that differs from protein or peptide based approaches.